HC Wainwright Issues Pessimistic Outlook for OKUR Earnings

OnKure Therapeutics (NASDAQ:OKUR - Free Report) - HC Wainwright cut their Q1 2025 EPS estimates for OnKure Therapeutics in a research report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.41) per share for the quarter, down from their previous estimate of ($1.19). HC Wainwright has a "Buy" rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics' current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics' Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

Several other equities research analysts have also weighed in on OKUR. Oppenheimer decreased their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a report on Tuesday, March 11th. Leerink Partners initiated coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They issued an "outperform" rating and a $33.00 price target on the stock. Finally, Leerink Partnrs raised shares of OnKure Therapeutics to a "strong-buy" rating in a report on Thursday, December 5th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $32.33.

OnKure Therapeutics Stock Performance

Shares of OKUR traded down $0.09 during mid-day trading on Thursday, hitting $4.96. The stock had a trading volume of 11,964 shares, compared to its average volume of 84,814. OnKure Therapeutics has a 52 week low of $4.45 and a 52 week high of $20.00. The stock's fifty day moving average price is $5.39. The company has a market capitalization of $66.64 million, a price-to-earnings ratio of -0.41 and a beta of 0.28.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.51).

Institutional Investors Weigh In On OnKure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of OKUR. Highbridge Capital Management LLC bought a new position in shares of OnKure Therapeutics in the fourth quarter valued at approximately $3,438,000. Geode Capital Management LLC bought a new position in OnKure Therapeutics in the 4th quarter valued at $659,000. Aisling Capital Management LP purchased a new stake in shares of OnKure Therapeutics in the fourth quarter worth $762,000. Aldebaran Capital LLC bought a new stake in OnKure Therapeutics during the fourth quarter valued at $392,000. Finally, Renaissance Technologies LLC purchased a new position in OnKure Therapeutics during the fourth quarter worth about $408,000. 90.98% of the stock is currently owned by institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.